Published in Am J Transplant on March 23, 2010
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int (2015) 1.92
Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant (2013) 1.11
Management of patients with hepatitis B in special populations. World J Gastroenterol (2015) 0.93
Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl (2013) 0.83
The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation. Langenbecks Arch Surg (2011) 0.79
Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation. Gastroenterol Hepatol (N Y) (2014) 0.79
Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcome. World J Gastroenterol (2014) 0.79
Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients. World J Gastrointest Pharmacol Ther (2015) 0.78
Large fragment pre-S deletion and high viral load independently predict hepatitis B relapse after liver transplantation. PLoS One (2012) 0.78
Hepatitis B immune globulin in liver transplantation prophylaxis: an update. Hepat Mon (2012) 0.76
Progress in hepatitis B: a 30-year journey through three continents. Hepatology (2014) 0.76
Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers. Hepatol Int (2011) 0.76
Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol (2015) 0.76
Posttransplant prophylaxis strategies for hepatitis B. Am J Transplant (2010) 0.75
Clinicopathological features of hepatitis B virus recurrence after liver transplantation: eleven-year experience. Int J Clin Exp Pathol (2014) 0.75
Prophylaxis of hepatitis B infection in solid organ transplant recipients. Therap Adv Gastroenterol (2013) 0.75
Hepatitis: viral load predicts HBV recurrence after liver transplant. Nat Rev Gastroenterol Hepatol (2010) 0.75
Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. Transplantation (2015) 0.75
Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. J Clin Transl Hepatol (2016) 0.75
Prophylactic managements of hepatitis B viral infection in liver transplantation. World J Gastroenterol (2016) 0.75
Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med (1993) 4.43
Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology (1998) 2.19
Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation (1996) 2.09
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology (2007) 1.49
Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology (2002) 1.33
A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology (2001) 1.29
Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl (2006) 1.29
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology (2008) 1.27
Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol (2008) 1.25
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol (2006) 1.25
Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol (2001) 1.19
High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol (1999) 1.17
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl (2005) 1.10
A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol (2006) 1.08
Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl (2005) 1.06
An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl (2000) 1.05
Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl (2000) 1.04
Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl (2002) 1.02
Management of hepatitis B in liver transplant recipients. J Viral Hepat (2007) 0.99
Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant (2003) 0.95
Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl (2006) 0.90
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl (2006) 0.88
Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol (2007) 0.87
Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation (2008) 0.87
Management of hepatitis B in liver transplantation patients. Semin Liver Dis (2004) 0.85
Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut (2001) 0.82
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Structure of yeast phenylalanine tRNA at 3 A resolution. Nature (1974) 10.27
New rapid gel sequencing method for RNA. Nature (1977) 9.56
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
Structure of nucleosome core particles of chromatin. Nature (1977) 6.24
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med (1995) 4.84
The primary structure of transcription factor TFIIIA has 12 consecutive repeats. FEBS Lett (1985) 4.73
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med (1989) 4.69
Structure of yeast phenylalanine transfer RNA at 2.5 A resolution. Proc Natl Acad Sci U S A (1975) 4.57
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53
The crystal structure of EcoRV endonuclease and of its complexes with cognate and non-cognate DNA fragments. EMBO J (1993) 4.11
A controlled trial of scheduled replacement of central venous and pulmonary-artery catheters. N Engl J Med (1992) 3.95
Outcomes of stroke patients in Medicare fee for service and managed care. JAMA (1997) 3.91
A crystallographic study of metal-binding to yeast phenylalanine transfer RNA. J Mol Biol (1977) 3.71
Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med (1996) 3.38
Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet (1997) 3.11
Estimating hospital costs. A multiple-output analysis. J Health Econ (1986) 3.09
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther (2012) 2.89
Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med (1979) 2.82
Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology (1994) 2.81
Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg (1999) 2.79
Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. JAMA (1999) 2.78
Current methods of transfer of young people with Type 1 diabetes to adult services. Diabet Med (2002) 2.76
Further refinement of the structure of yeast tRNAPhe. J Mol Biol (1978) 2.71
Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med (1997) 2.69
Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology (1999) 2.64
Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant (2008) 2.63
Degradation of collagen by a human granulocyte collagenolytic system. J Clin Invest (1968) 2.62
The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition. Lancet (1968) 2.61
Fetus in fetu: a case report and literature review. Pediatrics (2000) 2.52
Pneumocystis carinii hepatitis in the acquired immunodeficiency syndrome (AIDS) Ann Intern Med (1989) 2.42
Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med (2001) 2.41
Current trends in colorectal cancer: site, incidence, mortality and survival in England and Wales. Clin Oncol (R Coll Radiol) (2001) 2.41
Hodgkin's disease. Immunologic, clinical, and histologic features of 50 untreated patients. Ann Intern Med (1967) 2.38
Right lobe living donor liver transplantation. Transplantation (1999) 2.31
Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med (1978) 2.29
Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood (2001) 2.26
World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat (2002) 2.26
Crystallographic and biochemical investigation of the lead(II)-catalyzed hydrolysis of yeast phenylalanine tRNA. Biochemistry (1985) 2.22
Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology (2000) 2.21
Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology (1993) 2.20
Vegetative infection of transjugular intrahepatic portosystemic shunts. Gastroenterology (1998) 2.20
Indeterminate hepatitis C. Lancet (1993) 2.17
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Failure of Centers for Disease Control criteria to identify hepatitis B infection in a large municipal obstetrical population. Ann Intern Med (1987) 2.14
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13
A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology (1999) 2.11
Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation (1996) 2.09
Prostaglandin E1 administration following orthotopic liver transplantation: a randomized prospective multicenter trial. Gastroenterology (1996) 2.07
Detection and surveillance of colorectal cancer. JAMA (1989) 2.07
Alfentanil for conscious sedation during colonoscopy. South Med J (1995) 2.07
Hepatitis C-associated hepatocellular carcinoma. Hepatology (1990) 2.07
Relief of uremic pruritus with ultraviolet phototherapy. N Engl J Med (1977) 2.06
Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol (2000) 2.06
Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther (2006) 2.04
Database comparison of the adult-to-adult living donor liver transplantation cohort study (A2ALL) and the SRTR U.S. Transplant Registry. Am J Transplant (2010) 2.04
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat. J Clin Invest (1972) 2.00
Variation in organ quality between liver transplant centers. Am J Transplant (2011) 1.99
A model for the tertiary structure of the 28 residue DNA-binding motif ('zinc finger') common to many eukaryotic transcriptional regulatory proteins. Protein Eng (1988) 1.98
Atomic co-ordinates for yeast phenylalanine tRNA. Nucleic Acids Res (1975) 1.98
The advantage of sex in the RNA virus phi6. Genetics (1997) 1.94
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Pb(II)-catalysed cleavage of the sugar-phosphate backbone of yeast tRNAPhe--implications for lead toxicity and self-splicing RNA. Nature (1983) 1.92
Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol (2000) 1.90
The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc (1996) 1.89
Validation of a recording spectrophotometric method for measurement of membrane-associated Mg- and NaK-ATPase activity. J Lab Clin Med (1979) 1.86
Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant (2006) 1.83
X-ray diffraction study of a new crystal form of the nucleosome core showing higher resolution. J Mol Biol (1981) 1.81
Large cystic lesions of the liver in adults: a 15-year experience in a tertiary center. J Am Coll Surg (2001) 1.79
The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology (1997) 1.74
Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg (2001) 1.72
Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant (2007) 1.70
Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL Retrospective Cohort Study. Am J Transplant (2008) 1.69
Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review. Radiographics (1993) 1.68
Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther (2004) 1.68
Human granulocyte collagenase. Science (1968) 1.68
Evaluation of monovalent influenza vaccine in a retirement community during the epidemic of 1965-66. JAMA (1969) 1.67
Differing roles for zinc fingers in DNA recognition: structure of a six-finger transcription factor IIIA complex. Proc Natl Acad Sci U S A (1998) 1.67
Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med (1995) 1.67
The home health visit: an appropriate unit for Medicare payment? Health Aff (Millwood) (1996) 1.67
Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl (2007) 1.64
Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am (2006) 1.64
Liver transplantation for patients with alcoholism and end-stage liver disease. Am J Gastroenterol (1993) 1.64
Clinical relevance of thyroid-stimulating autoantibodies in pediatric graves' disease-a multicenter study. J Clin Endocrinol Metab (2014) 1.63
Fatal Clostridium difficile enteritis after total abdominal colectomy. J Clin Gastroenterol (1996) 1.63
Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol (1997) 1.62